Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital

Infection

Volumn 45, Issue 4, 2017, Pages 425-431

  Pichenot, Marie ^a   Héquette Ruz, Rozenn ^a   Le Guern, Remi ^a   Grandbastien, Bruno ^a   Charlet, Clément ^a   Wallet, Frédéric ^a   Schiettecatte, Sophie ^a   Loeuillet, Fanny ^a   Guery, Benoit ^a,b   Galperine, Tatiana ^a  

^a UNIV LILLE   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Clinical practice; Clostridium difficile; Fidaxomicin; Prospective

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE; CLOSTRIDIUM INFECTION; DRUG EFFECTS; FRANCE; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; UNIVERSITY HOSPITAL;

AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 85010750371     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-017-0981-8     Document Type: Article

References (48)

1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–34.
2. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81:1–14.
3. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–208.
4. Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014;14:1208–19.
5. Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current status of the treatment of fulminant colitis. Cir Esp. 2015;93:276-82.
6. Hensgens MPM, Dekkers OM, Goorhuis A, LeCessie S, Kuijper EJ. Predicting a complicated course of Clostridium difficile infection at the bedside. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20:O301–8.
7. Taori SK, Wroe A, Poxton IR. Clostridium difficile infections in South East Scotland: mortality and recurrence in a region without PCR ribotype 027. J Med Microbiol. 2013;62:1468–77.
8. Le Monnier A, Duburcq A, Zahar J-R, et al. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. Infect: J Hosp; 2015.
9. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2015;21:164–70.
10. Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, Marcil-Héguy A, Nault V, Valiquette L. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62:574–80.
11. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2386–8.
12. Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:452–60.
13. D’Agostino RB, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;58:1386–93.
14. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One. 2014;9:e98400.
15. Bacci S, Mølbak K, Kjeldsen MK, Olsen KEP. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis. 2011;17:976–82.
16. Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2013;17:118–24 (discussion 124–125).
17. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18:21–7.
18. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;45:302–7.
19. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55:S162–9.
20. Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol. 2011;60:1213–7.
21. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55:S132–42.
22. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281–9.
23. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.
24. Debast SB, Bauer MP, Kuijper EJ. Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20:1–26.
25. Khanafer N, Barbut F, Eckert C, et al. Factors predictive of severe Clostridium difficile infection depend on the definition used. Anaerobe. 2016;37:43–8.
26. Jacobson SM, Slain D. Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 2015;72:1871–5.
27. Eiland EH, Sawyer AJ, Massie NL. Fidaxomicin use and clinical outcomes for Clostridium difficile-associated diarrhea. Infect Dis Clin. Pract Baltim Md. 2015;23:32–5.
28. Vargo CA, Bauer KA, Mangino JE, Johnston JEW, Goff DA. An antimicrobial stewardship program’s real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series. Pharmacotherapy. 2014;34:901-9.
29. Fehér C, Múñez Rubio E, Merino Amador P, et al. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort. Eur J Clin Microbiol Infect Dis. 2016. [Epub ahead of print].
30. Goldenberg SD, Brown S, Edwards L, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2016;35:251–9.
31. Esmaily-Fard A, Tverdek FP, Crowther DM, Ghantoji SS, Adachi JA, Chemaly RF. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer. Pharmacotherapy. 2014;34:1220-5.
32. Orenstein R. Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55:613–4.
33. Johnson S, Gerding DN. Fidaxomicin ‘chaser’ regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56:309–10.
34. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136:1206–14.
35. Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144:433–9 (discussion 439–440).
36. Penziner S, Dubrovskaya Y, Press R, Safdar A. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:1776–81.
37. van Kleef E, Green N, Goldenberg SD, et al. Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach. J Hosp Infect. 2014;88:213–7.
38. Dubberke ER, Butler AM, Reske KA, et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis. 2008;14:1031–8.
39. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ Can Med Assoc J J Assoc Med Can. 2005;173:1037–42.
40. Reigadas E, Alcalá L, Marín M, Martín A, Iglesias C, Bouza E. Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting. Epidemiol Infect. 2016;144:268–73.
41. Pilate T, Verhaegen J, Van Ranst M, Saegeman V. Binary toxin and its clinical importance in Clostridium difficile infection, Belgium. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2016;35:1741–7.
42. Goldenberg SD, French GL. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect. 2011;62:355–62.
43. Watt M, McCrea C, Johal S, Posnett J, Nazir J. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection. 2016;44:599–606.
44. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IAO. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother. 2014;69:2901–12.
45. Rubio-Terrés C, Cobo Reinoso J, Grau Cerrato S, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2015;34:2213–23.
46. Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis. 2013;13:936–45.
47. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175:1792–801.
48. Kok J, Wang Q, Thomas LC, Gilbert GL. Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution. J Clin Microbiol. 2011;49:3719–21.